The Comprehensive Center for Stem Cells and Reconstructive Medicine, with the deployment of accelerators, innovative cores, specialized laboratories, and training services, provides the basis for the development of technologies, commercialization of products and services in this field. In this center, 5 reconstructive medicine accelerators are located including Ava Restoration, Yes Gene Yar, Bomix, Persis Gene Par, and Liogen Farmed.

 Sorena Sattari, Vice President of Science and Technology, said at the inauguration ceremony of the collection of accelerators, clean rooms, and the unveiling of the knowledge-based products of the Comprehensive Center for Stem Cells and Reconstructive Medicine, referring to our country's progress in this field with the creativity of educated youth. It serves as a model for other universities to support academics' innovative ideas and move in that direction.

 The head of the Stem Cell Science and Technology Development Headquarters and Reconstructive Medicine, referring to the production of Iranian knowledge-based products in the treatment of cancer, added: "A great deal of work has been done in the field of cancer treatment. And if successful in the human phase, it will enter the market.

Sattari pointed to the unveiling of more than 30 new and advanced medical knowledge-based products at the event and added: "Some of the products unveiled in the world are new or have not even been commercialized." Great work has been done with the production of these technological products, and the creation of this ecosystem in and around the university to create great changes is valuable and appreciated.

The head of the National Elites Foundation called these companies a platform for attracting top talents and non-resident Iranian elites and said: "These centers are a platform for attracting elites." Now many elites have returned to the country. The ceremony was followed by the unveiling of a clean room and a set of accelerators from the Comprehensive Stem Cell Center of the established knowledge-based products.

 The turnover of this field is about $8.3 billion and 90 companies and 160 centers in the United States provide case cell technology for cell therapy. The results of the animal phase have been effective and have shown positive results in the treatment of cancer mice.

Report by the Communication and Information Center in the Vice Presidency of Science and Technology